Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/25/2022 | $2.00 | Buy → Neutral | Goldman |
| 1/24/2022 | $13.00 → $6.00 | Buy | B. Riley Securities |
| 1/6/2022 | $7.00 → $8.00 | Neutral → Buy | Goldman Sachs |
| 8/20/2021 | $7.00 | Neutral | Goldman |
| 8/3/2021 | $16.00 → $7.00 | Overweight → Neutral | JP Morgan |
| 7/22/2021 | $21.00 → $19.00 | Buy | B. Riley Securities |
| 6/29/2021 | $20.00 | Overweight | Cantor Fitzgerald |
S-1/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
Goldman downgraded Magenta Therapeutics from Buy to Neutral and set a new price target of $2.00
B. Riley Securities reiterated coverage of Magenta Therapeutics with a rating of Buy and set a new price target of $6.00 from $13.00 previously
Goldman Sachs upgraded Magenta Therapeutics from Neutral to Buy and set a new price target of $8.00 from $7.00 previously